Top 10 Early Stage Investors in Biotechnology, Pharma & Life Sciences
| Rank | Investor Name |
|---|---|
| 1 | RA Capital Management |
| 2 | ORBIMED Healthcare Fund Management |
| 3 | ARCH Venture Partners |
| 4 | Camden Partners |
| 5 | Eli Lilly and Company |
| 6 | Even One Ventures |
| 7 | Andreessen Horowitz - a16z |
| 8 | Atlas Ventures |
| 9 | Frazier Healthcare Partners |
| 10 | Novo Holdings |
Early stage activity in this category is led by institutional venture franchises and category specialists. Platform science and pharma partnership appetite drive the category, with specialist funds leading most rounds. For a company raising a priced early round, this list identifies the firms with the most active recent presence in the category.
The CapitalDart directory identifies the right person to contact at each of these firms, with their individual investment criteria.
Create a free account and get the contacts for the investors above.
Rankings cover January 2025 to July 2026 investment activity in US and Canada companies. Seed and early-stage rankings measure deal participation, not suitability for every raise.